Sanofi Exceeds Earnings and Revenue Estimates, Raises FY26 Outlook
Sanofi reported second-quarter results that exceeded both top-line revenue and bottom-line earnings estimates. The company's non-GAAP EPS came in at €2.09 per share, surpassing expectations by €0.19, while total revenue reached €11.6 billion—up 16.1% year-over-year—and beat forecasts by €710 million. Strong performance was driven primarily by its pharmaceutical launches and Dupixent sales. Pharma launch sales surged by 48.3%, reaching €1.3 billion, led by Ayvakit, Altuvii O, and Sarclisa. Dupixent's revenue hit a record high of €5.2 billion for the quarter—marking its first time exceeding €5 billion per quarter—and grew year-over-year by 37.6%. However, vaccine sales declined slightly to €1.1 billion due to a strong prior period driven by influenza vaccines. Sanofi also raised its full-year guidance for FY2026, forecasting around 10% revenue growth at constant exchange rates (CER), with business EPS expected to grow faster than sales.
Tickers: $SNY
Topics: ayvakit dupixent pharmaceuticals revenue_growth sarclisa